NBPF member 17, pseudogeneGenealiases: NBPF23 · NBPF23P
Q-omics provides the consensus-scored NBPF17P profile across patient tissues and cancer cell-line models. NBPF17P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NBPF17P is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, NBPF17P RNA expression shows 13,228 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, HNSC, and THYM as cancer lineages where NBPF17P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NBPF17P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NBPF17P survival associations across molecular data types. NBPF17P RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NBPF17P RNA expression–survival associations across cancer types. High NBPF17P expression shows unfavorable associations in STAD, THCA and TGCT, but favorable associations in UCS, ACC and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify UCS as the clearest survival context for NBPF17P RNA expression.
This table summarizes NBPF17P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NBPF17P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NBPF17P shows lower tumor expression in LUAD, UCEC, LUSC and KICH and higher tumor expression in HNSC and PRAD. The HNSC box plot shows higher NBPF17P RNA expression in tumor versus normal tissue (log2 FC = +0.033, t-test p = .001).
This table shows molecular features associated with NBPF17P in patient tissues and cancer cell lines. In patient samples, NBPF17P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
